A Pilot Trial of Jawarish Amla as Adjuvant to Anti-Tubercular Treatment Drugs for Control of Adverse Reactions in DOTS Regime in Pulmonary TB Patients

Authors

  • Arish Mohammad Khan Sherwani PSM (Unani), National Institute of Unani Medicine
  • Muhammad Zulkifle National Institute of Unani Medicine, Bangalore, India
  • Rehmatulla Mohammad Saleha Ministry of Health and Family Welfare, Karnataka State Government, Bangalore, India

DOI:

https://doi.org/10.5915/44-1-9988

Keywords:

Pulmonary Tuberculosis, Side Effects, Drug Resistance, Herbal Medicine, Adverse Reaction, Jawarish Amla

Abstract

DOI: http://dx.doi.org/10.5915/44-1-9988

Background and objectives: One of the greatest challenges of health care systems at the dawn of the 21st century is tuberculosis (TB). Drug resistant strains of TB are becoming a global public health risk. These strains commonly appear due to faulty therapies. Patients frequently stop treatment due to the toxicity of anti-tubercular treatment (ATT) drugs. Amla (Emblica officinalis) is a well-known Unani single drug. Jawarish amla is a Unani compound formulation which is commonly used to administer amla. This study tested the efficacy of jawarish amla as an adjuvant to ATT drugs in reducing their side effects.

Methodology: Half of forty eligible pulmonary tuberculosis patients were randomly assigned to Test (Group B) and the other half to Control (Group A). Six grams of jawarish amla twice daily was administered to the test group, and the same dosage of placebo was administered to control group along with directly observed treatment, short course chemotherapy (DOTS) for 60 days. Fisher exact test and paired t-test were applied for efficacy evaluation. Grading of symptoms was done to assess the toxicity of ATT and outcome of the adjuvant.

Results and discussion: Significant improvements were observed in almost all subjective and objective parameters. The exceptions were serum creatine and serum uric acid, which showed non-significant slight elevations within normal limits.

Conclusion: Jawarish amla was ascertained to be safe and effective adjuvant of DOTS in combating the adverse effects of ATT drugs.

Author Biographies

Arish Mohammad Khan Sherwani, PSM (Unani), National Institute of Unani Medicine

Head of Department and Reader, Preventive and Social Medicine/community medicine [Unani(greeko-Arab)]

Muhammad Zulkifle, National Institute of Unani Medicine, Bangalore, India

MD (Kulliyat), Professor Department of Kulliyat (Fundamentals of Unani),National Institute of Unani Medicine, Bangalore, India

Rehmatulla Mohammad Saleha, Ministry of Health and Family Welfare, Karnataka State Government, Bangalore, India

MD (PSM),Unani Medical Officer, Ministry of health and family welfare,Karnataka State Government, Bangalore, India (Was PG Scholar,Batch 2008-2009, National Institute of Unani Medicine, Bangalore, India (Note: Rehmatulla is the full name in all official documents)

Downloads

Additional Files

Published

2013-02-12

Issue

Vol. 44 No. 1 (2012)

Section

Original Articles

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).